Inhibition of the CDK2 and Cyclin A complex leads to autophagic degradation of CDK2 in cancer cells

• DOI: 10.1038/s41467-022-30264-0
• Publication Date: 2022-05-20T10:04:24Z
• Authors: Jiawei Zhang; Yichao Gan; Hongzhi Li; Jie Yin; Xin He; Liming Lin; Senlin Xu; Zhipeng Fang; Byung-wook Kim; Lina Gao; Lili Ding; Eryun Zhang; Xiaoxiao Ma; Junfeng Li; Ling Li; Yang Xu; David Horne; Rongzhen Xu; Hua Yu; Ying Gu; Wendong Huang
• Keywords: 0301 basic medicine; Leukemia; Science; Q; Cyclin-Dependent Kinase 2; Cyclin A; Article; Cyclin-Dependent Kinases; 3. Good health; Mice; 03 medical and health sciences; Ribonucleoproteins; Cell Line, Tumor; Cyclins; Autophagy; CDC2-CDC28 Kinases; Animals; Humans; Homoharringtonine

AbstractCyclin-dependent kinase 2 (CDK2) complex is significantly over-activated in many cancers. While it makes CDK2 an attractive target for cancer therapy, most inhibitors against CDK2 are ATP competitors that are either nonspecific or highly toxic, and typically fail clinical trials. One alternative approach is to develop non-ATP competitive inhibitors; they disrupt interactions between CDK2 and either its partners or substrates, resulting in specific inhibition of CDK2 activities. In this report, we identify two potential druggable pockets located in the protein-protein interaction interface (PPI) between CDK2 and Cyclin A. To target the potential druggable pockets, we perform a LIVS in silico screening of a library containing 1925 FDA approved drugs. Using this approach, homoharringtonine (HHT) shows high affinity to the PPI and strongly disrupts the interaction between CDK2 and cyclins. Further, we demonstrate that HHT induces autophagic degradation of the CDK2 protein via tripartite motif 21 (Trim21) in cancer cells, which is confirmed in a leukemia mouse model and in human primary leukemia cells. These results thus identify an autophagic degradation mechanism of CDK2 protein and provide a potential avenue towards treating CDK2-dependent cancers.